Abbott to Acquire Exact Sciences in $21 Billion Agreement
The deal positions Abbott to enter the US cancer screening and precision oncology diagnostics market with products including Cologuard and Oncotype DX tests.
Read MorePosted by CLP Edit Staff | Nov 21, 2025 | Company News |
The deal positions Abbott to enter the US cancer screening and precision oncology diagnostics market with products including Cologuard and Oncotype DX tests.
Read MorePosted by CLP Edit Staff | Nov 21, 2025 | Covid 19, Flu & Respiratory Infections |
The company aims to support FDA 510(k) clearance submission for its point-of-care platform detecting flu A/B, COVID-19, and RSV.
Read MorePosted by CLP Edit Staff | Nov 19, 2025 | Company News |
The association’s incoming CEO brings more than two decades of leadership experience in global health, nonprofit management, and the scientific community.
Read MorePosted by CLP Edit Staff | Nov 14, 2025 | Infectious Diseases |
The multiplex PCR assay achieved 100% accuracy while reducing turnaround time for histoplasmosis, blastomycosis, and coccidioidomycosis diagnosis.
Read MorePosted by CLP Edit Staff | Nov 14, 2025 | Infectious Diseases |
The droplet digital PCR assay shows 90.9% sensitivity and can detect previously missed cases of the bacterial infection.
Read More